Abstract
BackgroundDue to conflicting evidence regarding first-line therapies for chronic post-surgical pain (CPSP), here we comparatively evaluated the efficacy and safety of first-line therapies for the prevention of CPSP.Materials and MethodsMEDLINE, EMBASE, and Cochrane CENTRAL databases were searched for randomized, controlled trials (RCTs) of systemic drugs measuring pain three months or more post-surgery. Pairwise meta-analyses (a frequentist technique directly comparing each intervention against placebo) and network meta-analyses (a Bayesian technique simultaneously comparing several interventions via an evidence network) compared the mean differences for primary efficacy (reduction in all pain), secondary efficacy (reduction in moderate or severe pain), and primary safety (drop-out rate from treatment-related adverse effects). Ranking probabilities from the network meta-analysis were transformed using surface under the cumulative ranking analysis (SUCRA). Sensitivity analyses evaluated the impact of age, gender, surgery type, and outlier studies.ResultsTwenty-four RCTs were included. Mexiletine and ketamine ranked highest in primary efficacy, while ketamine and nefopam ranked highest in secondary efficacy. Simultaneous SUCRA-based rankings of the interventions according to both efficacy and safety revealed that nefopam and mexiletine ranked highest in preventing CPSP. Through the sensitivity analyses, gabapentin and ketamine remained the most-highly-ranked in terms of efficacy, while nefopam and ketamine remained the most-highly-ranked in terms of safety.ConclusionsNefopam and mexiletine may be considered as first-line therapies for the prevention of CPSP. On account of the paucity of evidence available on nefopam and mexiletine, gabapentin and ketamine may also be considered. Venlafaxine is not recommended for the prevention of CPSP.
Highlights
Chronic post-surgical pain (CPSP) is a pain syndrome characterized by pain at the surgical site that continues at least two months post-surgery after all other etiologies have been excluded [1]
Simultaneous surface under the cumulative ranking analysis (SUCRA)-based rankings of the interventions according to both efficacy and safety revealed that nefopam and mexiletine ranked highest in preventing chronic post-surgical pain (CPSP)
Gabapentin and ketamine remained the mosthighly-ranked in terms of efficacy, while nefopam and ketamine remained the mosthighly-ranked in terms of safety
Summary
Chronic (or persistent) post-surgical pain (CPSP) is a pain syndrome characterized by pain at the surgical site that continues at least two months post-surgery after all other etiologies have been excluded (e.g., chronic infection, malignancy, etc.) [1]. A more recent 2012 meta-analysis by Clarke et al on the use of gabapentinoids for the prevention of CPSP showed that both gabapentin and pregabalin therapy demonstrated significant reductions in CPSP [7]. In contrast to Clarke et al.’s findings, Chaparro et al.’s meta-analysis showed a significant reduction in the incidence of CPSP following treatment with ketamine at three months and six months after surgery but showed no such effect with either gabapentin or pregabalin [8]. The aim of this network meta-analysis was to comparatively evaluate the efficacy and safety of firstline therapies for the prevention of CPSP. Due to conflicting evidence regarding first-line therapies for chronic post-surgical pain (CPSP), here we comparatively evaluated the efficacy and safety of first-line therapies for the prevention of CPSP
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
